Trial win sets up filings for Lilly’s diabetes blockbuster hope tirzepatideEli Lilly has scored five out of five with its phase 3 trials of type 2 diabetes candidate Share XTrial win sets up filings for Lilly’s diabetes blockbuster hope tirzepatidehttps://pharmaphorum.com/news/final-trial-win-sets-up-filings-for-lillys-diabetes-blockbuster-hope-tirzepatide/
Better Therapeutics begins ‘real world’ study of digital diabetes therapyAfter announcing plans to go public, prescription digital therapeutics (DTx) firm Better Therapeutics has begun a “real world” Share XBetter Therapeutics begins ‘real world’ study of digital diabetes therapyhttps://pharmaphorum.com/news/better-therapeutics-begins-real-world-study-of-digital-diabetes-therapy/
Bayer data for kidney disease hope finerenone sets up filingsBayer’s blockbuster ambitions for diabetic kidney disease (DKD) drug candidate finerenone look a lot firmer with the publication Share XBayer data for kidney disease hope finerenone sets up filingshttps://pharmaphorum.com/news/bayer-data-for-kidney-disease-hope-finerenone-sets-up-filings/
Novo launches type 2 diabetes pill in UK after NICE waives reviewNovo Nordisk has launched its type 2 diabetes pill Rybelsus (semaglutide) in the UK, after cost-effectiveness watchdog NICE Share XNovo launches type 2 diabetes pill in UK after NICE waives reviewhttps://pharmaphorum.com/news/novo-launches-type-2-diabetes-pill-in-uk/
NHS backs free behavioural change app for type 2 diabeticsNHS England has awarded a contract to tech company Changing Health to develop a free app to help Share XNHS backs free behavioural change app for type 2 diabeticshttps://pharmaphorum.com/news/nhs-backs-free-behavioural-change-app-for-type-2-diabetics/
FDA fast-tracks Lilly/Boehringer’s Jardiance in chronic kidney diseaseThe FDA has granted a speedy review of Eli Lilly and Boehringer Ingelheim’s Jardiance for a potential new Share XFDA fast-tracks Lilly/Boehringer’s Jardiance in chronic kidney diseasehttps://pharmaphorum.com/news/fda-fast-tracks-lilly-boehringers-jardiance-in-chronic-kidney-disease/
Lilly, Boehringer bag FDA okay for diabetes triple Trijardy XREli Lilly and Boehringer Ingelheim’s longstanding alliance in diabetes has delivered another new product, this time a three-drug Share XLilly, Boehringer bag FDA okay for diabetes triple Trijardy XRhttps://pharmaphorum.com/news/lilly-boehringer-bag-fda-okay-for-diabetes-triple-trijardy-xr/
AZ’s Forxiga gets heart claim data on its EU labelAstraZeneca has been cleared to include cardiovascular and kidney outcomes data on the label of its type 2 Share XAZ’s Forxiga gets heart claim data on its EU labelhttps://pharmaphorum.com/news/azs-forxiga-gets-heart-claim-data-on-its-eu-label/
Novo Nordisk’s Victoza gets FDA okay for paediatric useNovo Nordisk’s GLP-1 agonist Victoza has become the first non-insulin drug to be approved in the US as Share XNovo Nordisk’s Victoza gets FDA okay for paediatric usehttps://pharmaphorum.com/news/novo-nordisks-victoza-fda-paediatric-use/
